Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Cefodizime: Third-Generation Cephalosporin Antibiotic for...

    2026-03-18

    Cefodizime: Third-Generation Cephalosporin Antibiotic for Broad-Spectrum Antibacterial Research

    Executive Summary: Cefodizime is a broad-spectrum, third-generation cephalosporin antibiotic that targets penicillin-binding proteins (PBPs) to disrupt bacterial cell wall synthesis, demonstrating efficacy against diverse Gram-positive and Gram-negative bacteria, including Escherichia coli and Haemophilus influenzae (Jiang et al., 2025). It is stable against β-lactamases and exhibits an 81% plasma protein binding rate. With MIC90 values as low as 0.40 mg/L for E. coli, Cefodizime is suitable for infection models requiring precise antibacterial activity quantification. The compound is primarily excreted renally, making it kidney-safe, and offers immunomodulatory properties by enhancing phagocytic function. APExBIO supplies Cefodizime (BA1050) for advanced microbiology research (product page).

    Biological Rationale

    Cefodizime belongs to the third-generation cephalosporin antibiotics, designed to maximize antibacterial spectrum while retaining safety for clinical and research use (Cefodizime: Broad-Spectrum Third-Generation Cephalosporin...). It is structurally optimized for stability against β-lactamase enzymes. This property enables its activity against pathogens resistant to earlier cephalosporin generations. Cefodizime is validated for efficacy in both Gram-positive (e.g., methicillin-sensitive Staphylococcus aureus, streptococci) and Gram-negative (e.g., Enterobacteriaceae, Haemophilus influenzae, Neisseria spp.) infection models (Jiang et al., 2025). The immunomodulatory properties of Cefodizime, including enhancement of phagocyte function, distinguish it from most β-lactam antibiotics (Cefodizime in Translational Research: Mechanistic Insight...). Its primary route of elimination is renal, with a 24-hour urinary excretion rate of 56–80%, supporting its classification as a kidney-safe antibiotic (Cefodizime: Broad-Spectrum Cephalosporin for Microbiology...).

    Mechanism of Action of Cefodizime

    Cefodizime exerts bactericidal effects by binding to penicillin-binding proteins (PBPs), particularly PBPs 1A/B, 2, and 3 in Escherichia coli (Jiang et al., 2025). This interaction disrupts the transpeptidation step in peptidoglycan synthesis, leading to bacterial cell wall lysis. The compound is highly stable against hydrolysis by common β-lactamases, which broadens its activity profile compared to earlier cephalosporins. Cefodizime’s immunomodulatory actions are evidenced by enhanced phagocytic cell function in vitro and in vivo (Cefodizime: Rethinking Broad Spectrum Antibiotic Strategi...). This dual role—direct antibacterial and immunomodulatory—makes it applicable in infectious disease research where both pathogen and host responses are measured.

    Evidence & Benchmarks

    • Cefodizime exhibits MIC90 values of 0.40 mg/L for Escherichia coli and <0.01 mg/L for Haemophilus influenzae under standard CLSI conditions (Jiang et al., 2025).
    • 24-hour urinary excretion rate is 56–80% in healthy adult volunteers at a standard dose of 1–2 g, indicating predominant renal elimination (APExBIO Product Page).
    • Plasma protein binding rate is 81%, influencing pharmacokinetics and tissue distribution (APExBIO Product Page).
    • Cefodizime retains activity against most β-lactamase-producing strains, but is ineffective against extended-spectrum β-lactamase (ESBL) producers and methicillin-resistant Staphylococcus aureus (MRSA) (Jiang et al., 2025).
    • In psychiatric hospital surveillance (2022), Cefodizime was among the most commonly used antibiotics for both respiratory and urinary tract infections (Jiang et al., 2025).

    This article provides an updated synthesis of outcomes and mechanistic detail compared to Cefodizime: Broad-Spectrum Third-Generation Cephalosporin..., extending the discussion with new resistance surveillance data and workflow integration tools.

    Applications, Limits & Misconceptions

    Cefodizime is suited for:

    • Antibacterial activity assays against clinical and laboratory strains of Gram-positive and Gram-negative bacteria.
    • Modeling of respiratory and urinary tract infections in preclinical and translational research (Cefodizime in Translational Infectious Disease Research: ...—this article adds detailed immunomodulatory benchmarks not found in the linked review).
    • Studies of β-lactamase stability and resistance development.
    • Exploration of immunomodulation in infectious disease models.

    Common Pitfalls or Misconceptions

    • Ineffectiveness against ESBL and MRSA: Cefodizime is not active against extended-spectrum β-lactamase (ESBL)-producing bacteria or methicillin-resistant Staphylococcus aureus (MRSA).
    • Solubility limitations: The compound is insoluble in water and ethanol; DMSO is required for dissolution at ≥51.1 mg/mL.
    • Contraindication in cephalosporin allergy: Do not use in patients or models with known cephalosporin hypersensitivity.
    • Not suitable for long-term solution storage: Solutions degrade; store solid at -20°C and prepare fresh working solutions as needed.
    • Limited activity against certain resistant Gram-negative strains: Some Enterobacteriaceae with advanced resistance mechanisms may not be susceptible.

    Workflow Integration & Parameters

    APExBIO’s Cefodizime (BA1050) is supplied as a research-grade solid, recommended for storage at -20°C. For microbiology assays, dissolve in DMSO to achieve working concentrations; do not use water or ethanol as solvents. Standard MIC testing employs concentrations from 0.008 to 64 mg/L, adjusted to the tested organism. Renal excretion and high plasma protein binding should be considered in in vivo models. Dosage and administration routes (i.m., i.v.) depend on experimental protocol, with reference values available in the product datasheet. Avoid repeated freeze-thaw of aliquots. Adverse effects in animal models include gastrointestinal and cutaneous reactions, as well as injection site irritation. The integration of Cefodizime in Gram-positive and Gram-negative bacterial infection models enhances reproducibility and resistance benchmarking (Cefodizime in Translational Research: Mechanistic Insight...—this article provides updated workflow protocols).

    Conclusion & Outlook

    Cefodizime remains a critical tool for the scientific study of bacterial pathogenesis, resistance, and antibiotic efficacy. Its robust spectrum, β-lactamase stability, and immunomodulatory properties provide unique advantages for microbiology and translational research. However, awareness of its resistance boundaries and physicochemical limitations is essential for experimental design. Enhanced resistance monitoring and rational use are necessary to preserve Cefodizime's utility in infectious disease research (Jiang et al., 2025).